1 Department of Surgery, University Hospital Basel , University of Basel, Basel, Switzerland .
Tissue Eng Part A. 2014 Feb;20(3-4):842-53. doi: 10.1089/ten.TEA.2013.0372. Epub 2013 Nov 8.
Following the coordinated efforts of five established scientific organizations, this report describes the "novel cellular therapy" activity (i.e., cellular treatments excluding hematopoietic stem cells [HSC] for the reconstitution of hematopoiesis) in Europe for the year 2011. Two hundred forty-six teams from 35 countries responded to the cellular therapy survey, 126 teams from 24 countries provided data on 1759 patients using a dedicated survey and 120 teams reported no activity. Indications were musculoskeletal/rheumatological disorders (46%; 99% autologous), cardiovascular disorders (22%; 100% autologous), hematology/oncology, predominantly including the prevention or treatment of graft-versus-host disease (18%; 2% autologous), neurological disorders (2%; 83% autologous), gastrointestinal (1%; 68% autologous), and other indications (12%; 77% autologous). Autologous cells were used predominantly for musculoskeletal/rheumatological (58%) and cardiovascular (27%) disorders, whereas allogeneic cells were used mainly for hematology/oncology (84%). The reported cell types were mesenchymal stem/stromal cells (56%), HSC (23%), chondrocytes (12%), dermal fibroblasts (3%), keratinocytes (2%), and others (4%). In 40% of the grafts, cells were delivered following ex vivo expansion, whereas cells were transduced or sorted, respectively, in 3% and 10% of the reported cases. Cells were delivered intraorgan (42%), intravenously (26%), on a membrane or gel (16%), or using 3D scaffolds (16%). Compared to last year, the number of teams participating in the dedicated survey doubled and, for the first time, all European Group for Blood and Marrow Transplantation teams reporting information on cellular therapies completed the extended questionnaire. The data are compared with those collected since 2008 to identify trends in the field. This year's edition specifically focuses on cardiac cell therapy.
在五个知名科学组织的共同努力下，本报告描述了欧洲 2011 年“新型细胞疗法”活动（即除造血干细胞（HSC）以外用于重建造血的细胞疗法）。246 个来自 35 个国家的团队对细胞疗法调查做出了回应，126 个来自 24 个国家的团队提供了使用专用调查的 1759 名患者的数据，120 个团队报告无活动。适应症为肌肉骨骼/风湿病（46%；99%为自体）、心血管疾病（22%；100%为自体）、血液学/肿瘤学，主要包括预防或治疗移植物抗宿主病（18%；2%为自体）、神经疾病（2%；83%为自体）、胃肠道（1%；68%为自体）和其他适应症（12%；77%为自体）。自体细胞主要用于肌肉骨骼/风湿病（58%）和心血管疾病（27%），而异体细胞主要用于血液学/肿瘤学（84%）。报告的细胞类型为间充质干细胞/基质细胞（56%）、HSC（23%）、软骨细胞（12%）、真皮成纤维细胞（3%）、角质形成细胞（2%）和其他（4%）。在 40%的移植物中，细胞在体外扩增后被输送，而在报告病例中，分别有 3%和 10%的细胞被转导或分选。细胞被输送到器官内（42%）、静脉内（26%）、膜或凝胶上（16%）或使用 3D 支架（16%）。与去年相比，参与专用调查的团队数量增加了一倍，并且首次报告细胞疗法信息的所有欧洲血液和骨髓移植组织完成了扩展问卷。这些数据与自 2008 年以来收集的数据进行了比较，以确定该领域的趋势。今年的版本特别关注心脏细胞疗法。
